Mesoblast at Bell Potter Healthcare Conference: pipeline, sales and filings
Mesoblast Limited (MESO) used the Bell Potter Healthcare Conference to present a year of commercial progress and discuss its pipeline, which could bring several regulatory and clinical catalysts in the coming year. The company reported fiscal 2026 net revenues of $115 million and gross profit, excluding amortization, of $110 million.
RYONCIL, Mesoblast's FDA-approved allogeneic stem cell therapy, completed its first year of commercialization with more than 98% commercial insurance coverage and over 50 treatment centers onboarded. The company also completed treatment of 350 patients in its Phase III chronic low back pain trial, with a primary endpoint readout expected in mid-2027.
Mesoblast secured a $125 million five-year non-dilutive credit facility to consolidate and retire two higher-cost facilities, improving its debt structure while preserving cash for development work.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.